Particle.news
Download on the App Store

Rare Medication Abortion Failure Recounted in Germany as Access Debate Continues

The renewed account highlights the small failure risk of Mifegyne within Germany’s tightly regulated abortion law.

Overview

  • German outlets republished a first-person interview in which a woman remained pregnant in 2021 despite taking the morning-after pill and undergoing a medication abortion with Mifegyne.
  • At a follow-up visit, her doctor observed signs of an ongoing pregnancy, after which she chose to continue it and is now a mother, later reporting she has three children.
  • The reports note that Mifegyne fails in an estimated 2–4% of cases, underscoring a documented but uncommon medical outcome.
  • She says she supports access to abortion and does not regret seeking one, stressing that her positive experience with motherhood should not be generalized.
  • In background, abortion in Germany remains criminalized under §218 StGB except under defined exemptions, and a 2023 UN report and rights groups have criticized requirements such as mandatory counseling, waiting periods, and typical self-payment of costs.